• 15 June 2018

    Lanabecestat termination: another blow for BACE inhibitors

    After the disappointing failures of highly anticipated anti-amyloid pipeline drugs, such as Pfizer/Johnson & Johnson’s bapineuzumab and Eli Lilly’s solanezumab, the focus of research in Alzheimer’s has increasingly turned to...